{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:26Z","timestamp":1790155706750,"version":"4.0.1"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T00:00:00Z","timestamp":1434499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0128351","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T14:32:30Z","timestamp":1434551550000},"page":"e0128351","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rapid Immunochromatographic Detection of Serum Anti-\u03b1-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy"],"prefix":"10.1371","volume":"10","author":[{"given":"Sachie","family":"Nakano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsukimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayasu","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukuharu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Abiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Satou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Nakahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futoshi","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,6,17]]},"reference":[{"key":"ref1","first-page":"3733","article-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"RJ Desnick","year":"2001"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"DP Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"R Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"CM Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"CM Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"F Weidemann","year":"2009","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"C Tondel","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"PB Deegan","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy","volume":"92","author":"T Ohashi","year":"2007","journal-title":"Mol Genet Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"SM Rombach","year":"2012","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"WR Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"M Ries","year":"2006","journal-title":"Pediatrics"},{"issue":"Suppl B","key":"ref13","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0149-2918(08)80041-0","article-title":"The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative","volume":"30","author":"H Schellekens","year":"2008","journal-title":"Clin Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3390\/v4081235","article-title":"Updated values for molecular diagnosis for highly pathogenic avian influenza virus","volume":"4","author":"A Sakurai","year":"2012","journal-title":"Viruses"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1128\/JCM.00439-10","article-title":"Sensitivity of influenza rapid diagnostic tests to H5N1 and 2009 pandemic H1N1 viruses","volume":"48","author":"Y Sakai-Tagawa","year":"2010","journal-title":"J Clin Microbiol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e50670","DOI":"10.1371\/journal.pone.0050670","article-title":"Reliability of a newly-developed immunochromatography diagnostic kit for pandemic influenza A\/H1N1pdm virus: implications for drug administration","volume":"7","author":"T Sasaki","year":"2012","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"K Lee","year":"2003","journal-title":"Glycobiology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"GE Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg","volume":"2","author":"AC Vedder","year":"2007","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"AC Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ymgmr.2014.07.005","article-title":"Plasma mutant \u03b1-galactosidase A protein and globotriaosylsphingosine level in Fabry disease","volume":"1","author":"T Tsukimura","year":"2014","journal-title":"Mol Genet Reports"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0128351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T03:39:37Z","timestamp":1540265977000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0128351"}},"subtitle":[],"editor":[{"given":"Claudia","family":"Sommer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,17]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0128351","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,17]]}}}